BioSpace News Archive

Athersys, Inc. announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 21, 2022, the Company made an inducement grant to Daniel Camardo, the newly-appointed Chief Executive Officer of Athersys.

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that the Board of Directors has appointed Prakash Raman, Ph.D., as President, Chief Executive Officer and member of the Board of Directors.

Results from the investigational Phase III ARASENS trial have shown that the use of oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) and docetaxel significantly increased overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to ADT plus docetaxel.

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31, 2021.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that, effective February 16, 2022, its compensation committee approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to two individuals entering into employment with the Company.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions and services, reported fourth quarter and annual results for 2021.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the fourth quarter and full year ended December 31, 2021.

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2022, after the close of U.S.-based financial markets.

BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris Vinckier, to the Corporate Board, effective February 15, 2022.